[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Critique
June 2013

A Strong Argument for Improving Access Without DelayComment on “Delay in Surgical Treatment and Survival After Breast Cancer Diagnosis in Young Women by Race/Ethnicity”

Author Affiliations

Author Affiliation: Department of Surgery, Huntsman Cancer Hospital, University of Utah, Salt Lake City.

JAMA Surg. 2013;148(6):524. doi:10.1001/jamasurg.2013.1691

In this analysis of a large database, Smith et al1 explore the influence of delay in initiation of treatment for AYA women with breast cancer. Using the California Cancer Registry, Smith et al were able to determine time between diagnosis and initiation of treatment, whether that be surgery or chemotherapy. While difficult to sort out when so much information is presented as in this article, it was only a small subset of patients (those who got surgery only) in which the treatment delay (time from diagnosis to treatment of greater than 6 weeks) was associated in multivariate analysis with decreased survival (adjusted HR, 1.82; 95% CI, 1.21-2.74). Patients who received chemotherapy as part of their treatment were not found to have an independent association between treatment delay and survival. To provide further perspective, adjusted HRs for likelihood of death by cancer stage ranged from 3.14 for stage II to 24.51 for stage IV. Also, interestingly, race was an important predictor of survival for those who received chemotherapy in addition to surgery but not for those who received surgery only.

First Page Preview View Large
First page PDF preview
First page PDF preview
×